Guardant Health, Inc.
General ticker "GH" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $13.2B (TTM average)
Guardant Health, Inc. follows the US Stock Market performance with the rate: 53.9%.
Estimated limits based on current volatility of 2.8%: low 158.07$, high 167.30$
Factors to consider:
- Total employees count: 2506 (+24.0%) as of 2025
- US accounted for 94.0% of revenue in the fiscal year ended 2025-12-31
- Top business risk factors: Failure to achieve profitability, Strategic risks and growth management, Technology obsolescence, Labor/talent shortage/retention, Regulatory and compliance
- Current price 34.1% above estimated high
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [55.80$, 118.28$]
- 2026-12-31 to 2027-12-31 estimated range: [40.73$, 90.78$]
Financial Metrics affecting the GH estimates:
- Negative: with PPE of -30.8 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -1.45 <= 2.37
- Negative: negative Industry operating cash flow (median)
- Negative: negative Industry operating income (median)
- Negative: negative Net income
- Negative: 0 < Interest expense per share per price, % of 0.03
- Negative: 0.12 < Industry inventory ratio change (median), % of 0.16
- Negative: Shareholder equity ratio, % of -4.93 <= 7.04
- Negative: Investing cash flow per share per price, % of -4.91 <= -4.49
- Negative: -1.30 < Inventory ratio change, % of -1.14
Short-term GH quotes
Long-term GH plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $563.95MM | $739.02MM | $982.02MM |
| Operating Expenses | $1,128.67MM | $1,182.61MM | $1,419.27MM |
| Operating Income | $-564.73MM | $-443.59MM | $-437.25MM |
| Non-Operating Income | $85.96MM | $8.51MM | $19.71MM |
| Interest Expense | $2.58MM | $2.58MM | $3.90MM |
| R&D Expense | $367.19MM | $347.75MM | $364.19MM |
| Income(Loss) | $-478.76MM | $-435.09MM | $-417.54MM |
| Taxes | $0.69MM | $1.28MM | $-1.26MM |
| Net Income(Loss)* | $-479.45MM | $-436.37MM | $-416.28MM |
| Stockholders Equity | $158.68MM | $-139.65MM | $-99.31MM |
| Inventory | $61.95MM | $71.08MM | $85.88MM |
| Assets | $1,786.42MM | $1,485.61MM | $2,013.66MM |
| Operating Cash Flow | $-324.98MM | $-239.86MM | $-184.76MM |
| Capital expenditure | $20.49MM | $35.09MM | $48.31MM |
| Investing Cash Flow | $840.25MM | $-261.31MM | $-627.20MM |
| Financing Cash Flow | $477.38MM | $-1.00MM | $671.13MM |
| Earnings Per Share** | $-4.28 | $-3.56 | $-3.32 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.